about
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities.Tumor characteristics and prognosis in familial breast cancer.Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.Resistance to Anti-HER2 Therapies in Breast Cancer.HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study.The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis.Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysisGPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancerRibociclib in HR+/HER2- Advanced or Metastatic Breast Cancer PatientsThe oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceNeratinib in HER2-Positive Breast Cancer PatientsA CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast CancerHER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeFOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancerTowards personalized treatment for early stage HER2-positive breast cancerImmune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on TherapyA combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerTargeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast CancerEnhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistanceMetabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
P50
Q34570508-01F2553E-C703-4446-A07B-6E980DABB0BCQ36073658-BBC4759E-5269-4914-9BB7-783DB9C24207Q36207051-9A8A4B55-2B3B-4E55-A485-09348C6C7CB7Q36902056-3D10D226-E061-49EF-996F-3E09E147E071Q37013898-885CFA70-A815-4856-8FAE-3FB7E52AE9C0Q37707968-E811DBC7-B3E1-4138-A370-D461E585AE07Q38493878-5E8195BE-43BE-4D0C-835F-37233A1078A7Q38704133-5A467FF6-1224-48DA-9E14-1378C1489CF8Q38732455-F034CFDF-0C82-4115-BF93-5E52E6C50C9DQ39218132-2A7D1AF4-B34E-47FA-BF71-5CD9C244B82AQ39421814-2F353F31-9FFE-4DF1-866C-AA57965F9F4AQ44871921-2516A5C2-C170-4E9B-8911-8EDFC6D38381Q45494068-FC9B20D6-32E3-4286-91DD-EB917B6D99EAQ48578774-2D9B9427-FF0B-4A79-B893-FC4064738F84Q48935764-FC1FDB50-7366-4089-BBDC-F164DDEF674FQ49409380-4E390FBA-CEF5-4E91-8041-1B9F495C97BFQ49948404-FF6E4FEB-91FB-46E6-B207-64D7B3C0CB29Q64100928-89801C8C-2EFD-4FC9-951A-066EC7F14F5FQ88160433-10148A71-7AAA-42A3-A648-A0C27BA51650Q90311999-8C8600EB-7701-472B-8E98-1872E0B68E2BQ90568971-34FE4058-5506-4918-86A7-EFBDEA7ABF96Q90875656-08BE53DC-0337-435E-BBA8-51D98ABEA36AQ90946441-CD973406-7732-4C69-B19E-334A252A0C57Q91626887-E124F689-77D7-41F3-B0DE-C88C2CA72B6EQ91889799-379F08AE-4210-495D-88AF-FE6DB91B5447Q91974174-E92055EF-DC7F-4CE0-A652-DDD201417DB7Q92209204-6D919DA9-C96E-4AEE-B364-46953113BCE2Q92565256-BE07F005-3658-49DE-9E41-C56027A31ACEQ92667609-736365BE-EEF8-4F78-9265-6ED8400EC128Q95328259-F079BDE2-25B1-412A-A59E-539C61C1794CQ96157783-30A2E7AD-8F21-47C1-8DBD-7F035C2CD8D1
P50
description
investigador
@es
researcher
@en
name
Carmine De Angelis
@en
type
label
Carmine De Angelis
@en
prefLabel
Carmine De Angelis
@en
P31
P496
0000-0003-1158-4630